Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Shortly after Domagk and Hörlein announced their discovery of the antibacterial properties of the dye sulfamidochrysoidine (Prontosil) in 1935, numerous chemical companies set out to modify the chemical structure. They soon recognized the sulfa component as the true antibacterial and produced an incredible number of derivatives (more than 5000 different compounds!!) by 1945.[1, Continue reading The Rapid Rise of Sulfonamide Diversity
The development history of glycopeptide drugs is anything but normal. Daptomycin (Cubicin®) was abandoned by Lilly but resurrected by Francis Tally at Cubist by adjusting the dosing schedule to once daily and careful uptitration. The drug did superbly in a landmark endocarditis trial and everything looked rosy. Then we learned Continue reading Here They Are: Dalbavancin and Oritavancin – The New Long-Acting Lipoglycopeptides
The website “ClinicalTrials.gov” has become the first stop for many of us who need to check on trial activity of a particular drug. All larger human Phase 2 – 4 trials are listed there in quite some detail. While companies sometimes shy away from publishing full entry criteria or primary Continue reading And the Results are …Pending